Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma

@article{Mak2019PeptideRR,
  title={Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma},
  author={I. Mak and Aimee R. Hayes and B. Khoo and A. Grossman},
  journal={Neuroendocrinology},
  year={2019},
  volume={109},
  pages={287 - 298}
}
  • I. Mak, Aimee R. Hayes, +1 author A. Grossman
  • Published 2019
  • Medicine
  • Neuroendocrinology
  • At present there is no clinical guideline or standardised protocol for the treatment of metastatic or invasive phaeochromocytoma and paraganglioma (collectively known as PPGL) due to the rarity of the disease and the lack of prospective studies or extended national databases. Prognosis is mainly determined by genetic predisposition, tumour burden, rate of disease progression, and location of metastases. For patients with progressive or symptomatic disease that is not amenable to surgery, there… CONTINUE READING
    24 Citations
    Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
    • 18
    • PDF
    Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges
    Hepatic metastatic paraganglioma 12 years after retroperitoneal paraganglioma resection: a case report
    • 1

    References

    SHOWING 1-10 OF 83 REFERENCES
    Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
    • 55
    • PDF
    Radionuclide Therapy for Neuroendocrine Tumors
    • 75
    • PDF
    The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
    • 408
    • PDF